Pharma BD Deal Intelligence

Valo Health, Inc. / Montai Therapeutics, Inc.

2026 · Acquisition/Merger · Complete

Flagship Pioneering merged two of its AI-based drug discovery companies: Valo Health and Montai Therapeutics combined into a single company retaining the Valo Health name, led by Valo CEO and Flagship CEO-Partner Brian Alexander. The merger joins Valo's AI-enabled human causal biology and predictive chemistry with Montai's clinical-stage immunology and inflammation pipeline, led by MTAI-1025 and an oral STAT6 inhibitor for atopic dermatitis and other type 2 inflammatory diseases. Financial terms were not disclosed.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal.

Key facts

Related deals

See the full interactive analysis, sources & comparables →